title: Imatinib mesylate induced erythroderma: A rare case series.
abstract: Imatinib is a tyrosine kinase inhibitor approved as a first line treatment for chronic myeloid leukemia and gastrointestinal stromal tumors. Usually the drug is well-tolerated with hematological adverse effects being most commonly seen. Dermatological side effects are seen in 9.5-69% of patients on imatinib; majority of which are minor and self-limiting. We, hereby, report a case series of erythroderma occurring secondary to imatinib in two patients with chronic myeloid leukemia. Both the patients improved upon the discontinuation of the drug. The literature review revealed only six probable cases of erythroderma due to imatinib. So, this case series is being reported for the rarity of this adverse effect of imatinib.
authors.forename: Sumir
authors.initials: S
authors.lastname: Kumar
authors.forename: Bharat Bhushan
authors.initials: BB
authors.lastname: Mahajan
authors.affiliation: Department of Dermatology, Venereology and Leprology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Kaur
authors.forename: Raja Paramjeet Singh
authors.initials: RP
authors.lastname: Banipal
authors.forename: Amarbir
authors.initials: A
authors.lastname: Singh
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate